EGFR Testing for Metastatic Non-Small Cell Lung Cancer with Jonathan W. Riess, MD, MS: Case 2
EGFR Testing for Metastatic Non-Small Cell Lung Cancer with Jonathan W. Riess, MD, MS
Riess case 2:
A 73-year-old woman with progressing EGFR+ adenocarcinoma.
- A 73-year-old woman diagnosed with stage IV adenocarcinoma
- Based on her EGFR+ status, she was treated with erlotinib
- After 9 months her disease progressed, along with the presence of minor symptoms
- Tissue biopsy was impeded by the tumor’s location; therefore, cell-free DNA testing was ordered
- Based on the positive results for a T790M mutation, the patient was switched to osimertinib.
- Her disease continues to be well-controlled on second-line therapy
Related Videos
Related Content
FDA Grants Breakthrough Therapy Designation to Sunvozertinib in EGFR Exon20+ NSCLC
April 9th 2024Article
Sunvozertinib was granted breakthrough therapy designation by the FDA for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring an EGFR exon 20 insertion mutation.
Read More
